Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer

Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06858969 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 130 participants, started 2025-04-09 and due to reach its primary completion in 2026-01-08. Interventions recorded: Treatment group; Standard-of-care control group. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: "* Age ≥18 years and ≤75 years, regardless of gender; Histologically confirmed unresectable metastatic/recurrent colorectal adenocarcinoma; No prior systemic antitumor therapy received for metastatic/recurrent colorectal adenocarcinoma; For subjects who have received prior neoadjuvant/adjuvant therap". No results are recorded here; the registry entry is the source.